Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

Trial ID or NCT#

NCT01791894

Status

not recruiting iconNOT RECRUITING

Purpose

This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stop them from dividing

Official Title

An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Anthony Oro, MD, PhD
Anthony Oro, MD, PhD
Dermatologist, Hair loss specialist, Dermatologic oncologist, Cutaneous oncology specialist, Skin stem cell specialist
Eugene and Gloria Bauer Professor
A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD
Medical oncologist, Head and neck specialist, Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)

Contact us to find out if this trial is right for you.

Contact

ccto-office@stanford.edu
650-498-7061